Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Recruiting 82Completed 80Unknown 55Terminated 26Active not recruiting 12Not yet recruiting 10Withdrawn 5Suspended 2Enrolling by invitation 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Advanced Solid Tumor × Clear all
NCT06219499 2024-04-03

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

OncoC4, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05791474 2023-11-29

ATI-2231 in Advanced Solid Tumor Malignancies

Washington University School of Medicine

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05381935 2023-01-31

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Elpiscience Biopharma, Ltd.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04797468 2023-01-17

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Shanghai Henlius Biotech

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04878484 2022-09-02

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Athenex, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡